{
    "name": "darunavir",
    "comment": "Rx",
    "other_names": [
        "Prezista"
    ],
    "classes": [
        "HIV",
        "Protease Inhibitors"
    ],
    "source": "https://reference.medscape.com/drug/prezista-darunavir-342647",
    "pregnancy": {
        "common": [
            "The recommended dosage in pregnant patients is 600 mg taken with ritonavir 100 mg twice daily with food; darunavir 800 mg taken with ritonavir 100 mg once daily should only be considered in certain pregnant patients who are already on a stable darunavir 800 mg with ritonavir 100 mg once daily regimen prior to pregnancy, are virologically suppressed (HIV-1 RNA less than 50 copies per mL), and in whom a change to twice daily darunavir 600 mg with ritonavir 100 mg may compromise tolerability or compliance",
            "Prospective pregnancy data from APR are not sufficient to adequately assess risk of birth defects or miscarriage; available data from APR show no statistically significant difference in overall risk of major birth defects for darunavir and cobicistat compared with background rate for major birth defects of 2.7% in a U.S. reference population of Metropolitan Atlanta Congenital Defects Program (MACDP)",
            "Use of darunavir may reduce the efficacy of combined hormonal contraceptives and the progestin-only pill; advice patients using combined hormonal contraceptives or the progestin-only pill to use an effective alternative contraceptive method or add a barrier method of contraception; for co-administration with drospirenone, clinical monitoring recommended due to potential for hyperkalemia"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "The Centers for Disease Control and Prevention recommend that HIV-infected mothers not breastfeed their infants to avoid risking postnatal transmission of HIV",
            "There are no data on the presence of darunavir in human milk, the effects on the breastfed infant, or the effects on milk production; because of the potential for (1) HIV transmission (in HIV-negative infants), (2) developing viral resistance (in HIV-positive infants) and (3) serious adverse reactions in a breastfed infant, instruct mothers not to breastfeed if they are receiving darunavir"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Hypersensitivity"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Must be taken with ritonavir and food, since dose is based on the fact that darunavir is metabolized by CYP3A4 and ritonavir is a potent CYP3A4 inhibitor",
                "Severe skin reactions, accompanied by fever and/or elevations of transaminases reported (0.4%); Stevens-Johnson Syndrome (<0.1%), toxic epidermal necrolysis, drug rash with eosinophilia and systemic symptoms, and acute generalized exanthematous pustulosis also reported",
                "Caution with elderly patients",
                "Caution with hepatic impairment (not recommended if severe)",
                "Contains a sulfa moiety; monitor patients with a known sulfonamide allergy",
                "Increase in total cholesterol and triglycerides reported; screen before therapy and throughout treatment",
                "Pancreatitis reported; use caution in patients at risk for pancreatitis (those with elevated triglycerids, history of pancreatitis, or advanced HIV disease",
                "Risk of immune reconstitution syndrome",
                "Redistribution/accumulation of body fat, including central obesity, dorsocervical fat enlargement (buffalo hump), peripheral wasting, facial wasting, breast enlargement, and “cushingoid appearance” have been observed in patients receiving antiretroviral therapy",
                "Patients may develop new onset diabetes mellitus or hyperglycemia; initiation or dose adjustments of insulin or oral hypoglycemic agents may be required",
                "Patients with hemophilia may develop increased bleeding events",
                "Not for use in patients < 3 years of age; toxicity may occur"
            ],
            "specific": [
                {
                    "type": "Hepatoxicity",
                    "description": [
                        "Risk of hepatotoxicity including drug induced hepatitis: acute hepatitis, cytolytic hepatitis",
                        "Especially with preexisting liver dysfunction (chronic hepatitis B or C)",
                        "Interrupt or discontinue treatment if new/worsening liver dysfunction develops"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "alfuzosin",
            "description": {
                "common": "darunavir will increase the level or effect of alfuzosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "aprepitant",
            "description": {
                "common": "darunavir will increase the level or effect of aprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "carbamazepine will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with carbamazepine may result in loss of therapeutic effect and development of resistance to darunavir"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "cobimetinib",
            "description": {
                "common": "darunavir will increase the level or effect of cobimetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Avoid coadministration with strong CYP3A4 inhibitors with (increases cobimetinib systemic exposure by 6.7-fold)."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "conivaptan",
            "description": {
                "common": "darunavir will increase the level or effect of conivaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of conivaptan with strong CYP3A4 inhibitors is contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dihydroergotamine intranasal",
            "description": {
                "common": "darunavir will increase the level or effect of dihydroergotamine intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "dronedarone",
            "description": {
                "common": "darunavir will increase the level or effect of dronedarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elbasvir/grazoprevir",
            "description": {
                "common": "darunavir increases levels of elbasvir/grazoprevir by Other (see comment). Contraindicated. \nComment: Coadministration with strong OATP1B1/3 inhibitors may increase the risk of ALT elevations owing to a significant increase in grazoprevir plasma concentrations."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eliglustat",
            "description": {
                "common": "darunavir will increase the level or effect of eliglustat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors are contraindicated with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers; eliglustat is contraindiated if strong or moderate CYP2D6 inhibitors are given concomitantly with strong or moderate CYP3A inhibitors"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "darunavir, elvitegravir/cobicistat/emtricitabine/tenofovir DF. Other (see comment). Contraindicated. \nComment: Elvitegravir/cobicistat/emtricitabine/tenofovir is a complete regimen for HIV and should not be administered with other antiretrovirals."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "darunavir will increase the level or effect of ergoloid mesylates by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ergonovine",
            "description": {
                "common": "darunavir will increase the level or effect of ergonovine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "finerenone",
            "description": {
                "common": "darunavir will increase the level or effect of finerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "flibanserin",
            "description": {
                "common": "darunavir will increase the level or effect of flibanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of flibanserin with moderate or strong CYP3A4 inhibitors is contraindicated. Severe hypotension or syncope can occur."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "darunavir will increase the level or effect of fosaprepitant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "irinotecan",
            "description": {
                "common": "darunavir will increase the level or effect of irinotecan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "irinotecan liposomal",
            "description": {
                "common": "darunavir will increase the level or effect of irinotecan liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "isavuconazonium sulfate",
            "description": {
                "common": "darunavir will increase the level or effect of isavuconazonium sulfate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ivabradine",
            "description": {
                "common": "darunavir will increase the level or effect of ivabradine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of ivabradine with strong CYP3A4 inhibitors is contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lomitapide",
            "description": {
                "common": "darunavir increases levels of lomitapide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increases lomitapide levels several folds."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lonafarnib",
            "description": {
                "common": "darunavir will increase the level or effect of lonafarnib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Lonafarnib is a sensitive CYP3A4 substrate. Coadministration with strong or moderate CYP3A4 inhibitors is contraindicated. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lovastatin",
            "description": {
                "common": "darunavir will increase the level or effect of lovastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase systemic statin exposure and risk of myopathy, including rhabdomyolysis"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "lurasidone",
            "description": {
                "common": "darunavir increases levels of lurasidone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of lurasidone and strong CYP3A4 inhibitors is contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "mavacamten",
            "description": {
                "common": "darunavir will increase the level or effect of mavacamten by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors may increase mavacamten systemic exposure, resulting in heart failure due to systolic dysfunction. "
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "methylergonovine",
            "description": {
                "common": "darunavir will increase the level or effect of methylergonovine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "naloxegol",
            "description": {
                "common": "darunavir will increase the level or effect of naloxegol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration of naloxegol with strong CYP3A4 inhibitors can significantly increase naloxegol systemic exposure which may precipitate opioid withdrawal symptoms"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pacritinib",
            "description": {
                "common": "darunavir will increase the level or effect of pacritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenobarbital",
            "description": {
                "common": "phenobarbital will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with phenobarbital may result in loss of therapeutic effect and development of resistance to darunavir"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "phenytoin",
            "description": {
                "common": "phenytoin will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with phenytoin may result in loss of therapeutic effect and development of resistance to darunavir"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "pimozide",
            "description": {
                "common": "darunavir will increase the level or effect of pimozide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with phenytoin may result in loss of therapeutic effect and development of resistance to darunavir."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "ranolazine",
            "description": {
                "common": "darunavir will increase the level or effect of ranolazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for serious and/or life-threatening reactions."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "regorafenib",
            "description": {
                "common": "darunavir, regorafenib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Strong CYP3A4 inhibitors increase regorafenib levels and decrease exposure of the active metabolites M-2 and M-5."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin decreases levels of darunavir by increasing metabolism. Contraindicated. Contraindicated. May result in loss of antiviral efficacy and/or development of viral resistance."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "salmeterol",
            "description": {
                "common": "darunavir increases levels of salmeterol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "simvastatin",
            "description": {
                "common": "darunavir will increase the level or effect of simvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Increased risk for rhabdomyolysis with drugs that increase simvastatin systemic exposure"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "St John's Wort",
            "description": {
                "common": "St John's Wort will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Coadministration with St. John's Wort may result in loss of therapeutic effect and development of resistance to darunavir."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "triazolam",
            "description": {
                "common": "darunavir will increase the level or effect of triazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Triazolam and midazolam (PO) are extensively metabolized by CYP3A. Coadministration of triazolam or midazolam (PO) with darunavir/ritonavir may cause large increases in the concentrations of these benzodiazepines. Potential for serious and/or life-threatening events (eg, prolonged or increased sedation or respiratory depression)"
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "venetoclax",
            "description": {
                "common": "darunavir will increase the level or effect of venetoclax by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Use of strong CYP3A4 inhibitors is contraindicated with venetoclax during the initial ramp-up dosing phase. If a strong CYP3A inhibitor must be used after the ramp-up phase, reduce the venetoclax dose by at least 75%."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "voclosporin",
            "description": {
                "common": "darunavir will increase the level or effect of voclosporin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "abametapir",
            "description": {
                "common": "abametapir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. For 2 weeks after abametapir application, avoid taking drugs that are CYP3A4 substrates. If not feasible, avoid use of abametapir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "acalabrutinib",
            "description": {
                "common": "darunavir will increase the level or effect of acalabrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of acalabrutinib with strong CYP3A inhibitors. If a strong CYP3A inhibitor must be used short-term (eg, up to 7 days), temporarily interrupt treatment with acalabrutinib."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "adagrasib",
            "description": {
                "common": "darunavir will increase the level or effect of adagrasib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of adagrasib, a CYP3A4 substrate, with strong CYP3A4 inhibitors until adagrasib concentrations have reached steady-state (after ~8 days). If steady state is not reached, concomitant use of strong CYP3A4 inhibitors will increase adagrasib concentrations and risk of its toxicities"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ado-trastuzumab emtansine",
            "description": {
                "common": "darunavir increases levels of ado-trastuzumab emtansine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. DM1, the cytotoxic component, is metabolized mainly by CYP3A4; strong CYP3A4 inhibitors may increase DM1 exposure and toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "afatinib",
            "description": {
                "common": "darunavir increases levels of afatinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Reduce afatinib daily dose by 10 mg if not tolerated when coadministered with P-gp inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apalutamide",
            "description": {
                "common": "apalutamide will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of apalutamide, a strong CYP3A4 inducer, with drugs that are CYP3A4 substrates can result in lower exposure to these medications. Avoid or substitute another drug for these medications when possible. Evaluate for loss of therapeutic effect if medication must be coadministered. Adjust dose according to prescribing information if needed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "apixaban",
            "description": {
                "common": "darunavir will increase the level or effect of apixaban by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If taking apixaban dose >2.5 mg BID, decrease dose by 50% if coadministered with strong dual inhibitors of CYP3A4 and P-gp; if currently taking apixaban 2.5 mg PO BID, avoid coadministration with strong dual inhibitors of CYP3A4 and P-gp"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "avanafil",
            "description": {
                "common": "darunavir will increase the level or effect of avanafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. CYP3A4 inhibitors may reduce avanafil clearance increasing systemic exposure to avanafil; significantly increased levels may result in significant adverse events including severe hypotension, syncope, visual changes, and priapism. Coadministration with strong CYP3A4 is contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "avapritinib",
            "description": {
                "common": "darunavir will increase the level or effect of avapritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of avapritinib with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "axitinib",
            "description": {
                "common": "darunavir increases levels of axitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with strong CYP3A4 inhibitors, reduce axitinib dose by 50%."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bedaquiline",
            "description": {
                "common": "darunavir will increase the level or effect of bedaquiline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of bedaquiline with strong CYP3A4 inhibitors for >14 consecutive days, unless the benefit of treatment outweighs the risk"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "betibeglogene autotemcel",
            "description": {
                "common": "darunavir, betibeglogene autotemcel. Other (see comment). Avoid or Use Alternate Drug. \nComment: Do not take antiretroviral medications for at least 1 month before mobilization or expected duration for elimination of the medications, and until all cycles of apheresis are completed. Antiretroviral medications may interfere with manufacturing of apheresed cells."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosentan",
            "description": {
                "common": "bosentan will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. stop bosentan >36 hours prior to PI initiation and restart 10 days after PI initiation at 62.5 mg once daily or every other day."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bosutinib",
            "description": {
                "common": "darunavir increases levels of bosutinib by P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "brigatinib",
            "description": {
                "common": "darunavir will increase the level or effect of brigatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concomitant use of a strong CYP3A inhibitor cannot be avoided, reduce the brigatinib once daily dose by about 50% (ie, from 180 mg to 90 mg, or from 90 mg to 60 mg). After discontinuation of a strong CYP3A inhibitor, resume the brigatinib dose that was tolerated prior to initiating the strong CYP3A inhibitor."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "darunavir will increase the level or effect of bromocriptine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabergoline",
            "description": {
                "common": "darunavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabotegravir",
            "description": {
                "common": "darunavir, cabotegravir. Other (see comment). Avoid or Use Alternate Drug. \nComment: Cabotegravir plus rilpivirine is a complete regimen. Coadministration with other antiretroviral medications for treating HIV-1 infection is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cabozantinib",
            "description": {
                "common": "darunavir will increase the level or effect of cabozantinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of cabozantinib with strong CYP3A4 inhibitors.  If a strong CYP3A4 inhibitor is required, decrease cabozantinib dose by 40 mg/day (Cometriq) or by 20 mg/day (Cabometyx). Resume previous dose 2-3 days after strong CYP3A4 inhibitor discontinued."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "calcitriol",
            "description": {
                "common": "darunavir will increase the level or effect of calcitriol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ceritinib",
            "description": {
                "common": "darunavir increases levels of ceritinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid if possible; if concomitant use is unavoidable, reduce ceritinib dose by ~33%; after discontinuation of strong CYP3A inhibitor, resume at previous dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chloramphenicol",
            "description": {
                "common": "chloramphenicol will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cimetidine",
            "description": {
                "common": "cimetidine will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "cobicistat",
            "description": {
                "common": "cobicistat will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "colchicine",
            "description": {
                "common": "darunavir will increase the level or effect of colchicine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid use of colchicine with strong CYP3A4 inhibitors. If coadministration is necessary, decrease colchicine dose or frequency as recommended in prescribing information. Use of any colchicine product in conjunction with strong CYP3A4 inhibitors is contraindicated in patients with renal or hepatic impairment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "conjugated estrogens",
            "description": {
                "common": "darunavir will decrease the level or effect of conjugated estrogens by  unspecified interaction mechanism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "copanlisib",
            "description": {
                "common": "darunavir will increase the level or effect of copanlisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concomitant use with strong CYP3A inhibitors cannot be avoided, reduce copanlisib dose to 45 mg."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "darunavir increases levels of dabrafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "daridorexant",
            "description": {
                "common": "darunavir will increase the level or effect of daridorexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diazepam",
            "description": {
                "common": "darunavir increases levels of diazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.  Use alternatives if available."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dofetilide",
            "description": {
                "common": "darunavir increases levels of dofetilide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potential for increased toxicity. Use alternatives if available. Increased risk of QT prolongation and cardiac arrhythmias."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "edoxaban",
            "description": {
                "common": "darunavir will increase the level or effect of edoxaban by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Dose adjustment may be required with strong P-gp inhibitors. DVT/PE treatment: Decrease dose to 30 mg PO once daily. NVAF: No dose reduction recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with efavirenz may result in loss of therapeutic effect and development of resistance to darunavir"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elacestrant",
            "description": {
                "common": "darunavir will increase the level or effect of elacestrant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elbasvir/grazoprevir",
            "description": {
                "common": "darunavir will increase the level or effect of elbasvir/grazoprevir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "elivaldogene autotemcel",
            "description": {
                "common": "elivaldogene autotemcel, darunavir.\nEither decreases effects of the other by Other (see comment). Avoid or Use Alternate Drug. \nComment: Patients should not take antiretroviral medications for at least 1 month before initiating medications for stem cell mobilization, for the duration of the medications? elimination, and until all cycles of apheresis are completed."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "encorafenib",
            "description": {
                "common": "darunavir will increase the level or effect of encorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If concomitant use of a strong CYP3A4 inhibitor is unavoidable, reduce encorafenib dose to one-third of the dose (eg, reduce from 450 mg/day to 150 mg/day). After discontinuing the inhibitor for 3-5 elimination half-lives, resume previous encorafenib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "entrectinib",
            "description": {
                "common": "darunavir will increase the level or effect of entrectinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of strong CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministration unavoidable, reduce entrectinib dose to 100 mg/day for patients aged 12 y or older with BSA >1.50m2. Resume previous entrectinib dose after discontinuing strong CYP3A inhibitor for 3-5 elimination half-lives."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "enzalutamide",
            "description": {
                "common": "darunavir will increase the level or effect of enzalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erdafitinib",
            "description": {
                "common": "darunavir will increase the level or effect of erdafitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration with strong CYP3A4 inhibitors, monitor closely for adverse reactions and consider decreasing dose accordingly. If strong CYP3A4 inhibitor is discontinued, consider increasing erdafitinib dose in the absence of any drug-related toxicities."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergoloid mesylates",
            "description": {
                "common": "darunavir increases levels of ergoloid mesylates by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ergotamine",
            "description": {
                "common": "darunavir will increase the level or effect of ergotamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. \"Potential for serious and/or life-threatening reactions such as acute ergot toxicity characterized by peripheral vasospasm and ischemia of the extremities and other tissues. \""
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "darunavir will increase the level or effect of erythromycin base by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "darunavir will increase the level or effect of erythromycin ethylsuccinate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "darunavir will increase the level or effect of erythromycin lactobionate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "darunavir will increase the level or effect of erythromycin stearate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "estrogens conjugated synthetic",
            "description": {
                "common": "darunavir will decrease the level or effect of estrogens conjugated synthetic by  unspecified interaction mechanism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "etravirine",
            "description": {
                "common": "etravirine will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with nevirapine may result in loss of therapeutic effect and development of resistance to darunavir"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "everolimus",
            "description": {
                "common": "darunavir will increase the level or effect of everolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fedratinib",
            "description": {
                "common": "darunavir will increase the level or effect of fedratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid fedratinib coadministration with strong CYP3A4 inhibitors, decrease fedratinib dose to 200 mg/day. If CYP3A4 inhibitor discontinued, increase fedratinib dose to 300 mg/day for 2 weeks, and then 400 mg/day thereafter as tolerated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "felbamate",
            "description": {
                "common": "darunavir will increase the level or effect of felbamate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fexinidazole",
            "description": {
                "common": "darunavir will decrease the level or effect of fexinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unable to avoid coadministration, monitor fexinidazole for decreased efficacy owing to decreased plasma concentrations of active M1 and M2 metabolites. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "flutamide",
            "description": {
                "common": "darunavir will increase the level or effect of flutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluticasone intranasal",
            "description": {
                "common": "darunavir will increase the level or effect of fluticasone intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Strong CYP3A4 inhibitors may increase systemic corticosteroid adverse effects; monitor for signs/symptoms of high corticosteroid concentrations including Cushing type signs/symptoms."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "gilteritinib",
            "description": {
                "common": "darunavir will increase the level or effect of gilteritinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Consider alternatives to any strong CYP3A4 inhibitor when coadministered with gilteritinib. If such a combination cannot be avoided, closely monitor for gilteritinib-related adverse effects. Interrupt and reduce gilteritinib dosage in patients with serious or life-threatening toxicity."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glasdegib",
            "description": {
                "common": "darunavir will increase the level or effect of glasdegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Consider alternate therapies that are not strong CYP3A inhibitors or monitor for increased risk of adverse effects, including QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glecaprevir/pibrentasvir",
            "description": {
                "common": "darunavir will increase the level or effect of glecaprevir/pibrentasvir by  decreasing metabolism. Avoid or Use Alternate Drug. Avoid coadministration of glecaprevir/pibrentasvir with darunavir (P-gp and a strong CYP3A4 inhibitor). "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ibrutinib",
            "description": {
                "common": "darunavir increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of ibrutinib and strong CYP3A4 inhibitors. If a strong CYP3A4 inhibitor must be used short-term (eg, anti-infectives for =7 days), interrupt ibrutinib therapy until strong CYP3A4 inhibitor is discontinued."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "idelalisib",
            "description": {
                "common": "darunavir will increase the level or effect of idelalisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministered with strong CYP3A inhibitors, monitor for signs of idelalisib toxicity; follow recommendations for dosage modifications if adverse reactions occur"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "infigratinib",
            "description": {
                "common": "darunavir will increase the level or effect of infigratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ivosidenib",
            "description": {
                "common": "darunavir will increase the level or effect of ivosidenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of strong CYP3A4 inhibitors with ivosidenib or replace with alternate therapies. If coadministration of a strong CYP3A4 inhibitor is unavoidable, reduce ivosidenib dose to 250 mg qDay. If the strong inhibitor is discontinued, increase ivosidenib dose (after at least 5 half-lives of the strong CYP3A4 inhibitor) to the recommended dose of 500 mg qDay. Monitor for increased risk of QTc interval prolongation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ketoconazole",
            "description": {
                "common": "ketoconazole, darunavir.\nEither increases effects of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Specific dosage recommendations for ketoconazole are not available when coadministered with darunavir. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "larotrectinib",
            "description": {
                "common": "darunavir will increase the level or effect of larotrectinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lefamulin",
            "description": {
                "common": "darunavir will increase the level or effect of lefamulin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of lefamulin with strong CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lemborexant",
            "description": {
                "common": "darunavir will increase the level or effect of lemborexant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of lemborexant with moderate or strong CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "leniolisib",
            "description": {
                "common": "darunavir will increase the level or effect of leniolisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "levoketoconazole, darunavir.\nEither increases effects of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Specific dosage recommendations for ketoconazole are not available when coadministered with darunavir. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "levonorgestrel oral/ethinylestradiol/ferrous bisglycinate",
            "description": {
                "common": "darunavir, levonorgestrel oral/ethinylestradiol/ferrous bisglycinate. Other (see comment). Avoid or Use Alternate Drug. \nComment: Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lopinavir",
            "description": {
                "common": "lopinavir decreases levels of darunavir by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lorlatinib",
            "description": {
                "common": "darunavir will increase the level or effect of lorlatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministering lorlatinib with strong CYP3A inhibitors. If unavoidable, reduce lorlatinib dose by 25 mg/day. If strong CYP3A inhibitor discontinued, increase to previous lorlatinib (dose after 3 plasma half-lives of strong CYP3A inhibitor). See monograph for further details. "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lurbinectedin",
            "description": {
                "common": "darunavir will increase the level or effect of lurbinectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "macitentan",
            "description": {
                "common": "darunavir will increase the level or effect of macitentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministering macitentan with strong CYP3A4 inhibitors "
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "medroxyprogesterone",
            "description": {
                "common": "darunavir will decrease the level or effect of medroxyprogesterone by  unspecified interaction mechanism. Avoid or Use Alternate Drug. Oral formulation only"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mefloquine",
            "description": {
                "common": "darunavir increases levels of mefloquine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Potential for increased toxicity. Avoid coadministration during and for 15 weeks after discontinuing mefloquine. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "darunavir will increase the level or effect of metoclopramide intranasal by  affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Concurrent use of metoclopramide intranasal and strong CYP2D6 inhibitors is not recommended since the metoclopramide intranasal dose cannot be adjusted."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midazolam",
            "description": {
                "common": "darunavir will increase the level or effect of midazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated. Triazolam and midazolam (PO) are extensively metabolized by CYP3A. Coadministration of triazolam or midazolam (PO) with darunavir/ritonavir may cause large increases in the concentrations of these benzodiazepines. Potential for serious and/or life-threatening events (eg, prolonged or increased sedation or respiratory depression)"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midazolam intranasal",
            "description": {
                "common": "darunavir will increase the level or effect of midazolam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of strong CYP3A4 inhibitors with midazolam intranasal causes higher midazolam systemic exposure, which may prolong sedation."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midostaurin",
            "description": {
                "common": "darunavir will increase the level or effect of midostaurin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong CYP3A4 inhibitors cannot be avoided, monitor midostaurin for increased risk of adverse reactions, especially during the first week of treatment."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "mobocertinib",
            "description": {
                "common": "darunavir will increase the level or effect of mobocertinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "modafinil",
            "description": {
                "common": "darunavir will increase the level or effect of modafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nefazodone",
            "description": {
                "common": "darunavir will increase the level or effect of nefazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "neratinib",
            "description": {
                "common": "darunavir will increase the level or effect of neratinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of neratinib with strong/moderate CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nevirapine",
            "description": {
                "common": "nevirapine will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with nevirapine may result in loss of therapeutic effect and development of resistance to darunavir."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norgestimate",
            "description": {
                "common": "darunavir will decrease the level or effect of norgestimate by  unspecified interaction mechanism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olaparib",
            "description": {
                "common": "darunavir will increase the level or effect of olaparib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg (capsule) or 150 mg (tablet) PO BID.  Do not substitute tablets with capsules."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "omaveloxolone",
            "description": {
                "common": "darunavir will increase the level or effect of omaveloxolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If unavoidable, reduce omaveloxolone dose to 50 mg/day. Closely monitor and discontinue if adverse effects emerge."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir",
            "description": {
                "common": "darunavir will increase the level or effect of ombitasvir/paritaprevir/ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC)",
            "description": {
                "common": "ombitasvir/paritaprevir/ritonavir & dasabuvir (DSC) will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of Viekira Pak with darunavir/ritonavir is not recommended"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "osimertinib",
            "description": {
                "common": "darunavir will increase the level or effect of osimertinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of osimertinib with strong CYP3A4 inhibitors. If no other alternative treatment exists, monitor patient more closely for adverse effects."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "palbociclib",
            "description": {
                "common": "darunavir will increase the level or effect of palbociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of palbociclib with strong CYP3A inhibitors. If unable to avoid, reduce palbociclib dose to 75 mg/day."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pazopanib",
            "description": {
                "common": "darunavir will increase the level or effect of pazopanib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of pazopanib with strong CYP3A4 inhibitors if possible; if must coadminister, decrease pazopanib dose to 400 mg/day"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pemigatinib",
            "description": {
                "common": "darunavir will increase the level or effect of pemigatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce pemigatinib dose (refer to drug monograph dosage modifications). After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pemigatinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perampanel",
            "description": {
                "common": "darunavir will increase the level or effect of perampanel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pexidartinib",
            "description": {
                "common": "darunavir will increase the level or effect of pexidartinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong or moderate CYP3A4 inhibitors is unavoidable, reduce pexidartinib dose (refer to drug monograph dosage modifications). After discontinuing the CYP3A4 inhibitor for 3 elimination half-lives, may resume previous pexidartinib dose."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pomalidomide",
            "description": {
                "common": "darunavir increases levels of pomalidomide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ponatinib",
            "description": {
                "common": "darunavir increases levels of ponatinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Decrease ponatinib starting dose to 30 mg qDay if coadministration with strong CYP3A4 inhibitors cannot be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pralsetinib",
            "description": {
                "common": "darunavir will increase the level or effect of pralsetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quazepam",
            "description": {
                "common": "darunavir will increase the level or effect of quazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "red yeast rice",
            "description": {
                "common": "darunavir will increase the level or effect of red yeast rice by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. May increase creatine kinase levels and increase risk of myopathy or rhabdomyolysis; red yeast rice contains monocolin K (reportedly identical to lovastatin)"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ribociclib",
            "description": {
                "common": "darunavir will increase the level or effect of ribociclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If a strong CYP3A inhibitor must be coadministered with ribociclib, reduce the ribociclib starting dose to 400 mg/day."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifabutin",
            "description": {
                "common": "rifabutin will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifampin",
            "description": {
                "common": "rifampin will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine decreases levels of darunavir by increasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "rimegepant",
            "description": {
                "common": "darunavir will increase the level or effect of rimegepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "riociguat",
            "description": {
                "common": "darunavir will increase the level or effect of riociguat by  decreasing metabolism. Avoid or Use Alternate Drug. Coadministration of riociguat (substrate of CYP isoenzymes 1A1, 2C8, 3A, 2J2) with strong CYP inhibitors may require a decreased initial dose of 0.5 mg PO TID; monitor for signs of hypotension and reduce dose if needed"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "romidepsin",
            "description": {
                "common": "darunavir will increase the level or effect of romidepsin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with strong 3A4 inhibitors should be avoided if possible."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ruxolitinib",
            "description": {
                "common": "darunavir will increase the level or effect of ruxolitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Reduce ruxolitinib starting dose to 10 mg BID with platelet count 100 X 10^9/L or more and concurrent use of strong CYP3A4 inhibitors; avoid with platelet counts <100 X 10^9/L"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ruxolitinib topical",
            "description": {
                "common": "darunavir will increase the level or effect of ruxolitinib topical by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Reduce ruxolitinib starting dose to 10 mg BID with platelet count 100 X 10^9/L or more and concurrent use of strong CYP3A4 inhibitors; avoid with platelet counts <100 X 10^9/L"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir decreases levels of darunavir by increasing metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selpercatinib",
            "description": {
                "common": "darunavir will increase the level or effect of selpercatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "selumetinib",
            "description": {
                "common": "darunavir will increase the level or effect of selumetinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with strong or moderate CYP3A4 inhibitors cannot be avoided, reduce selumetinib dosage (refer to selumetinib monograph for further information). After discontinuation of the strong or moderate CYP3A4 inhibitor for 3 elimination half-lives, resume selumetinib dose that was taken before initiating the inhibitor."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "silodosin",
            "description": {
                "common": "darunavir will increase the level or effect of silodosin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "siponimod",
            "description": {
                "common": "darunavir will increase the level or effect of siponimod by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of siponimod with a moderate or strong CYP3A4 inhibitor PLUS a moderate or strong CYP2C9 inhibitor is not recommended."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sonidegib",
            "description": {
                "common": "darunavir will increase the level or effect of sonidegib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sonidegib with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "sparsentan",
            "description": {
                "common": "darunavir, sparsentan.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. If unavoidable, interrupt treatment with sparsentan. When resuming sparsentan, consider dose titration. ."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "suvorexant",
            "description": {
                "common": "darunavir increases levels of suvorexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Suvorexant not recommended with use of strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tadalafil",
            "description": {
                "common": "darunavir will increase the level or effect of tadalafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Adjust tadalafil dose for PAH; if on cobicistat, start tadalafil 20 mg/day and may increase up to 40 mg/day; avoid tadalafil when starting cobicistat; for ED, may take a single dose of tadalafil not exceeding 10 mg in 72 hr."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tamoxifen",
            "description": {
                "common": "darunavir, tamoxifen. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. CYP3A4 inhibition decreases metabolism of tamoxifen to N-desmethyl tamoxifen (active metabolite with similar biologic activity)."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tamsulosin",
            "description": {
                "common": "darunavir increases levels of tamsulosin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "darunavir will increase the level or effect of tazemetostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of tazemetostat with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "teniposide",
            "description": {
                "common": "darunavir will increase the level or effect of teniposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ticagrelor",
            "description": {
                "common": "darunavir increases levels of ticagrelor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Ticagrelor is metabolized by CYP3A4/5. Avoid use with strong CYP3A inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tofacitinib",
            "description": {
                "common": "darunavir increases levels of tofacitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Reduce tofacitinib dose to 5 mg qDay when coadministered with potent CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tolvaptan",
            "description": {
                "common": "darunavir will increase the level or effect of tolvaptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "topotecan",
            "description": {
                "common": "darunavir will increase the level or effect of topotecan by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. Product labeling for PO topotecan recommends avoiding concomitant use of P-gp inhibitors; the interaction with IV topotecan may be less severe but is still likely of clinical significance"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trabectedin",
            "description": {
                "common": "darunavir will increase the level or effect of trabectedin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If strong CYP3A inhibitor must be used, short-term (eg, less than 14 days), administer  strong CYP3A inhibitor 1 week after trabectedin infusion, and discontinue the day prior to next trabectedin infusion"
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tucatinib",
            "description": {
                "common": "tucatinib will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid concomitant use of tucatinib with CYP3A substrates, where minimal concentration changes may lead to serious or life-threatening toxicities. If unavoidable, reduce CYP3A substrate dose according to product labeling."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ubrogepant",
            "description": {
                "common": "darunavir will increase the level or effect of ubrogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ulipristal",
            "description": {
                "common": "darunavir will increase the level or effect of ulipristal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vemurafenib",
            "description": {
                "common": "darunavir increases levels of vemurafenib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "venetoclax",
            "description": {
                "common": "darunavir will increase the level or effect of venetoclax by  P-glycoprotein (MDR1) efflux transporter. Avoid or Use Alternate Drug. If a P-gp inhibitor must be used, reduce the venetoclax dose by at least 50%. Monitor more closely for signs of venetoclax toxicities."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vilazodone",
            "description": {
                "common": "darunavir increases levels of vilazodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If intolerable adverse effects occur when coadministered with moderate CYP3A4 inhibitors, reduce daily dose to 20 mg."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "vorapaxar",
            "description": {
                "common": "darunavir increases levels of vorapaxar by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voriconazole",
            "description": {
                "common": "darunavir will increase the level or effect of voriconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "voxelotor",
            "description": {
                "common": "voxelotor will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Voxelotor increases systemic exposure of sensitive CYP3A4 substrates. Avoid coadministration with sensitive CYP3A4 substrates with a narrow therapeutic index. Consider dose reduction of the sensitive CYP3A4 substrate(s) if unable to avoid."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "abemaciclib",
            "description": {
                "common": "darunavir will increase the level or effect of abemaciclib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong CYP3A4 inhibitors increase plasma levels of abemaciclib and its metabolites. Abemaciclib dose reduction required. If a strong CYP3A4 inhibitor is discontinued, increase abemaciclib to the dose prior to initiating the strong inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "acarbose",
            "description": {
                "common": "darunavir decreases effects of acarbose by pharmacodynamic antagonism. Use Caution/Monitor. New onset  or exacerbation of diabetes mellitus and hyperglycemia  have been reported with  protease inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "albiglutide",
            "description": {
                "common": "darunavir decreases effects of albiglutide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "almotriptan",
            "description": {
                "common": "darunavir will increase the level or effect of almotriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alprazolam",
            "description": {
                "common": "darunavir will increase the level or effect of alprazolam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amiodarone",
            "description": {
                "common": "darunavir will increase the level or effect of amiodarone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amitriptyline",
            "description": {
                "common": "darunavir will increase the level or effect of amitriptyline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest feasible initial or maintenance dose). Monitor for antidepressant response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "darunavir will increase the level or effect of amlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amobarbital",
            "description": {
                "common": "amobarbital will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apalutamide",
            "description": {
                "common": "darunavir will increase the level or effect of apalutamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of apalutamide with strong CYP3A4 or CYP2C8 inhibitors does not require initial dosage modification; however, dose reduction may be needed based on tolerability."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aprepitant",
            "description": {
                "common": "aprepitant will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "darunavir will increase the level or effect of aripiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "armodafinil",
            "description": {
                "common": "armodafinil will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "artemether",
            "description": {
                "common": "darunavir, artemether. unknown mechanism. Use Caution/Monitor. Monitor for potential decrease of antimalarial efficacy or potential QT prolongation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "artemether/lumefantrine",
            "description": {
                "common": "darunavir will increase the level or effect of artemether/lumefantrine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Increased lumefantrine exposure may prolong QT interval"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atogepant",
            "description": {
                "common": "darunavir will increase the level or effect of atogepant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Recommended atogepant dosage is 10 mg PO qDay when coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "atorvastatin",
            "description": {
                "common": "darunavir will increase the level or effect of atorvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. For HMG-CoA reductase inhibitors that are not contraindicated with darunavir, dose should not  exceed 20 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bazedoxifene/conjugated estrogens",
            "description": {
                "common": "darunavir will increase the level or effect of bazedoxifene/conjugated estrogens by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "belzutifan",
            "description": {
                "common": "belzutifan will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If unable to avoid coadministration of belzutifan with sensitive CYP3A4 substrates, consider increasing the sensitive CYP3A4 substrate dose in accordance with its prescribing information. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzhydrocodone/acetaminophen",
            "description": {
                "common": "darunavir will increase the level or effect of benzhydrocodone/acetaminophen by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with strong CYP3A4 inhibitors may increase hydrocodone (benzhydrocodone is prodrug of hydrocodone) plasma concentrations and can result in potentially fatal respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "benzphetamine",
            "description": {
                "common": "darunavir will increase the level or effect of benzphetamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "betrixaban",
            "description": {
                "common": "darunavir increases levels of betrixaban by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. Decrease betrixaban dose to 80 mg PO once, then 40 mg PO qDay if coadministered with a P-gp inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bortezomib",
            "description": {
                "common": "darunavir will increase the level or effect of bortezomib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bosutinib",
            "description": {
                "common": "darunavir increases levels of bosutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong CYP3A4 inhibitors increases bosutinib plasma concentration ~5-fold."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brentuximab vedotin",
            "description": {
                "common": "darunavir increases levels of brentuximab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor patients for adverse reactions. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "brexpiprazole",
            "description": {
                "common": "darunavir will increase the level or effect of brexpiprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Administer half of the usual brexpiprazole dose when coadministered with strong CYP3A4 inhibitors. If also administered with a strong/moderate CYP2D6 inhibitor, administer a quarter of brexpiprazole dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "darunavir increases levels of bromocriptine by decreasing metabolism. Use Caution/Monitor. Increased levels possibly due to CYP3A4 inhibition."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "budesonide",
            "description": {
                "common": "darunavir will increase the level or effect of budesonide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine",
            "description": {
                "common": "darunavir increases levels of buprenorphine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Carefully titrate dose when initiating buprenorphine, buprenorphine/naloxone, or methadone with patients taking darunavir/cobicstat. When initiating cobicistat in patients taking buprenorphine, buprenorphine/naloxone, or methadone, adjust dose for  buprenorphine, buprenorphine/naloxone, or methadone and monitor clinical signs and symptoms."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine buccal",
            "description": {
                "common": "darunavir increases levels of buprenorphine buccal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Carefully titrate dose when initiating buprenorphine, buprenorphine/naloxone, or methadone with patients taking darunavir/cobicstat. When initiating cobicistat in patients taking buprenorphine, buprenorphine/naloxone, or methadone, adjust dose for  buprenorphine, buprenorphine/naloxone, or methadone and monitor clinical signs and symptoms."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine subdermal implant",
            "description": {
                "common": "darunavir will increase the level or effect of buprenorphine subdermal implant by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Monitor patients already on buprenorphine subdermal implant who require newly-initiated treatment with CYP3A4 inhibitors for signs and symptoms of overmedication. If the dose of the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, implant removal may be necessary and the patient should then be treated with a buprenorphine dosage form that permits dose adjustments. If a CYP3A4 inhibitor is discontinued in a patient who has been stabilized on buprenorphine, monitor the patient for withdrawal."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine transdermal",
            "description": {
                "common": "darunavir will increase the level or effect of buprenorphine transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buprenorphine, long-acting injection",
            "description": {
                "common": "darunavir will increase the level or effect of buprenorphine, long-acting injection by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Patients who transfer to buprenorphine long-acting injection from transmucosal buprenorphine coadministered with CYP3A4 inhibitors should be monitored to ensure buprenorphine plasma levels are adequate. Within 2 weeks, if signs and symptoms of buprenorphine toxicity or overdose occur and the concomitant CYP3A4 inhibitor cannot be reduced or discontinued, transition the patient back to a buprenorphine formulation that permits dose adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "buspirone",
            "description": {
                "common": "darunavir will increase the level or effect of buspirone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butabarbital",
            "description": {
                "common": "butabarbital will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "butalbital",
            "description": {
                "common": "butalbital will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cabazitaxel",
            "description": {
                "common": "darunavir increases levels of cabazitaxel by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Avoid coadministration."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "calcifediol",
            "description": {
                "common": "darunavir, calcifediol. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. CYP450 inhibitors may inhibit enzymes involved in vitamin D metabolism (CYP24A1 and CYP27B1). This may alter serum levels of calcifediol and decrease the conversion of calcifediol to calcitriol. Dose adjustment of calcifediol may be required, and serum 25­hydroxyvitamin D, intact PTH, and serum calcium concentrations should be closely monitored when initiating or discontinuing a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cannabidiol",
            "description": {
                "common": "darunavir will increase the level or effect of cannabidiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider reducing the cannabidiol dose when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "capmatinib",
            "description": {
                "common": "darunavir will increase the level or effect of capmatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carbamazepine",
            "description": {
                "common": "darunavir will increase the level or effect of carbamazepine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor plasma levels when used concomitantly"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cariprazine",
            "description": {
                "common": "darunavir will increase the level or effect of cariprazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with strong CYP3A4 inhibitors requires cariprazine dose reduction. See Dosage Modification section in drug monograph."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "carvedilol",
            "description": {
                "common": "darunavir will increase the level or effect of carvedilol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cenobamate",
            "description": {
                "common": "cenobamate will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Increase dose of CYP3A4 substrate, as needed, when coadministered with cenobamate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ceritinib",
            "description": {
                "common": "darunavir increases levels of ceritinib by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlordiazepoxide",
            "description": {
                "common": "darunavir increases levels of chlordiazepoxide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Potential for increased toxicity. Use alternatives if available. Consider lowering benzodiazepine dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "chlorpropamide",
            "description": {
                "common": "darunavir, chlorpropamide. Other (see comment). Use Caution/Monitor. \nComment: Darunavir may increase or decrease levels of chlorpropamide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciclesonide inhaled",
            "description": {
                "common": "darunavir increases levels of ciclesonide inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cilostazol",
            "description": {
                "common": "darunavir will increase the level or effect of cilostazol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cinacalcet",
            "description": {
                "common": "darunavir will increase the level or effect of cinacalcet by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "citalopram",
            "description": {
                "common": "darunavir will increase the level or effect of citalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest feasible initial or maintenance dose). Monitor for antidepressant response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider alternative antibiotics if clarithromycin coadministered with darunavir (plus ritonavir or cobicistat). If clarithromycin is necessary, no dose adjustment required with normal renal function; however, reduce clarithromycin dose by 50% with CrCl 30-60 mL/min and by 75%  with CrCl <30 mL/min. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clomipramine",
            "description": {
                "common": "darunavir will increase the level or effect of clomipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clonazepam",
            "description": {
                "common": "darunavir will increase the level or effect of clonazepam by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clopidogrel",
            "description": {
                "common": "darunavir will decrease the level or effect of clopidogrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Inhibition of CYP3A4 will reduce clopidogrel bioactivation"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clorazepate",
            "description": {
                "common": "darunavir increases levels of clorazepate by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely.  Use alternatives if available. Consider lowering benzodiazepine dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "clozapine",
            "description": {
                "common": "darunavir will increase the level or effect of clozapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conivaptan",
            "description": {
                "common": "conivaptan will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "conjugated estrogens, vaginal",
            "description": {
                "common": "darunavir will increase the level or effect of conjugated estrogens, vaginal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cortisone",
            "description": {
                "common": "darunavir will increase the level or effect of cortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crizotinib",
            "description": {
                "common": "darunavir increases levels of crizotinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Concomitant use of strong CYP3A inhibitors should be avoided.  ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "crofelemer",
            "description": {
                "common": "crofelemer increases levels of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Crofelemer has the potential to inhibit CYP3A4 at concentrations expected in the gut; unlikely to inhibit systemically because minimally absorbed."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "darunavir will increase the level or effect of cyclophosphamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "cyclosporine",
            "description": {
                "common": "cyclosporine will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabigatran",
            "description": {
                "common": "darunavir will increase the level or effect of dabigatran by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor. P-gp inhibitors may increase systemic exposure of dabigatran in patients with renal impairment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dabrafenib",
            "description": {
                "common": "dabrafenib will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "darifenacin",
            "description": {
                "common": "darifenacin will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dasatinib",
            "description": {
                "common": "darunavir will increase the level or effect of dasatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Dasatinib may require adjustment of dose or dosing interval if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deferasirox",
            "description": {
                "common": "deferasirox will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deflazacort",
            "description": {
                "common": "darunavir will increase the level or effect of deflazacort by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease deflazacort dose to one-third of the recommended dose if coadministered with moderate or strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "desvenlafaxine",
            "description": {
                "common": "darunavir increases levels of desvenlafaxine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "deutetrabenazine",
            "description": {
                "common": "darunavir will increase the level or effect of deutetrabenazine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Strong CYP2D6 inhibitors increase the systemic exposure to the active dihydro-metabolites of deutetrabenazine by approximately 3-fold. Do not exceed 18 mg/dose and 36 mg/day of deutetrabenazine if coadministered with strong CYP2D6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dexamethasone",
            "description": {
                "common": "darunavir will increase the level or effect of dexamethasone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dextroamphetamine transdermal",
            "description": {
                "common": "darunavir will increase the level or effect of dextroamphetamine transdermal by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Initiate with lower doses and monitor patients for signs and symptoms of serotonin syndrome, particularly during dextroamphetamine initiation and after a dosage increase. If serotonin syndrome occurs, discontinue dextroamphetamine transdermal and CYP2D6 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "DHEA, herbal",
            "description": {
                "common": "DHEA, herbal will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazepam intranasal",
            "description": {
                "common": "darunavir will increase the level or effect of diazepam intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong or moderate CYP3A4 inhibitors may decrease rate of diazepam elimination, thereby increasing adverse reactions to diazepam."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diazoxide",
            "description": {
                "common": "darunavir increases effects of diazoxide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "didanosine",
            "description": {
                "common": "darunavir will decrease the level or effect of didanosine by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Administer didanosine 1 hr before or 2 hr after darunavir/ritonavir."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dienogest/estradiol valerate",
            "description": {
                "common": "darunavir will increase the level or effect of dienogest/estradiol valerate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor.  Significant changes (increase or decrease) in plasma levels of estrogen and progestin have been seen when HIV protease inhibitors are administered. Monitor for potential adverse effects such as nausea, irregular uterine bleeding, breast tenderness and headache. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "darunavir will increase the level or effect of diltiazem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "disopyramide",
            "description": {
                "common": "darunavir will increase the level or effect of disopyramide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doravirine",
            "description": {
                "common": "darunavir will increase the level or effect of doravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of doravirine and CYP3A4 inhibitors may increase plasma concentrations and toxicities of doravirine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxepin cream",
            "description": {
                "common": "darunavir will increase the level or effect of doxepin cream by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin",
            "description": {
                "common": "darunavir will increase the level or effect of doxorubicin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxorubicin liposomal",
            "description": {
                "common": "darunavir will increase the level or effect of doxorubicin liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronabinol",
            "description": {
                "common": "darunavir will increase the level or effect of dronabinol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Dronabinol is a CYP3A4 substrate."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dronedarone",
            "description": {
                "common": "dronedarone will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "drospirenone",
            "description": {
                "common": "darunavir will increase the level or effect of drospirenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "duvelisib",
            "description": {
                "common": "darunavir will increase the level or effect of duvelisib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with a strong CYP3A4 inhibitor increases duvelisib AUC, which may increase the risk of duvelisib toxicities. Reduce duvelisib dose to 15 mg BID when coadministered with a strong CYP3A4 inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "efavirenz",
            "description": {
                "common": "darunavir and efavirenz both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elagolix",
            "description": {
                "common": "darunavir will increase the level or effect of elagolix by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of elagolix 200 mg BID with strong CYP3A inhibitors for >1 month is not recommended. Limit elagolix dose to 150 mg qDay and CYP3A inhibitor duration of use to 6 months if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eletriptan",
            "description": {
                "common": "darunavir will increase the level or effect of eletriptan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir",
            "description": {
                "common": "darunavir, elvitegravir. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Elvitegravir is a CYP3A4 substrate; unknown if darunavir will elevate levels; there are no data available to alter current dosing recommendations; recommended dose is elvitegravir 150 mg PO once daily with darunavir/ritonavir 600/100 mg PO BID."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "elvitegravir/cobicistat/emtricitabine/tenofovir DF",
            "description": {
                "common": "darunavir will increase the level or effect of elvitegravir/cobicistat/emtricitabine/tenofovir DF by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "encorafenib",
            "description": {
                "common": "encorafenib, darunavir. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Encorafenib both inhibits and induces CYP3A4 at clinically relevant plasma concentrations. Coadministration of encorafenib with sensitive CYP3A4 substrates may result in increased toxicity or decreased efficacy of these agents."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enfortumab vedotin",
            "description": {
                "common": "darunavir increases toxicity of enfortumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Enfortumab vedotin is an antibody-drug conjugate that releases monomethylauristatin E (MMAE) via proteolytic cleavage. MMAE is primarily metabolized by CYP3A4 in vitro. Coadministration with strong CYP3A4 inhibitors may increase free MMAE exposure, which may increase the incidence or severity of toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "enfuvirtide",
            "description": {
                "common": "darunavir and enfuvirtide both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erlotinib",
            "description": {
                "common": "darunavir will increase the level or effect of erlotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin base",
            "description": {
                "common": "erythromycin base will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin ethylsuccinate",
            "description": {
                "common": "erythromycin ethylsuccinate will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin lactobionate",
            "description": {
                "common": "erythromycin lactobionate will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "erythromycin stearate",
            "description": {
                "common": "erythromycin stearate will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eslicarbazepine acetate",
            "description": {
                "common": "eslicarbazepine acetate will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol",
            "description": {
                "common": "darunavir will increase the level or effect of estradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estradiol vaginal",
            "description": {
                "common": "darunavir will increase the level or effect of estradiol vaginal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with CYP3A4 inhibitors may increase plasma concentrations of estrogens and toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estrogens esterified",
            "description": {
                "common": "darunavir will increase the level or effect of estrogens esterified by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "estropipate",
            "description": {
                "common": "darunavir will increase the level or effect of estropipate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "eszopiclone",
            "description": {
                "common": "darunavir increases levels of eszopiclone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce eszopiclone starting dose to 1 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethinylestradiol",
            "description": {
                "common": "darunavir will decrease the level or effect of ethinylestradiol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Significant changes (increase or decrease) can occur in estrogen plasma levels. Efficacy of hormonal contraceptives may be reduced. Use of a nonhormonal contraceptive is recommended. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ethosuximide",
            "description": {
                "common": "darunavir increases levels of ethosuximide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etonogestrel",
            "description": {
                "common": "darunavir will increase the level or effect of etonogestrel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etoposide",
            "description": {
                "common": "darunavir will increase the level or effect of etoposide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "etravirine",
            "description": {
                "common": "darunavir will increase the level or effect of etravirine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable solution",
            "description": {
                "common": "darunavir decreases effects of exenatide injectable solution by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "exenatide injectable suspension",
            "description": {
                "common": "darunavir decreases effects of exenatide injectable suspension by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fedratinib",
            "description": {
                "common": "fedratinib will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Adjust dose of drugs that are CYP3A4 substrates as necessary."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "darunavir will increase the level or effect of felodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl",
            "description": {
                "common": "darunavir will increase the level or effect of fentanyl by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl intranasal",
            "description": {
                "common": "darunavir will increase the level or effect of fentanyl intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transdermal",
            "description": {
                "common": "darunavir will increase the level or effect of fentanyl transdermal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fentanyl transmucosal",
            "description": {
                "common": "darunavir will increase the level or effect of fentanyl transmucosal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. If coadministration of CYP3A4  inhibitors with fentanyl is necessary, monitor for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fesoterodine",
            "description": {
                "common": "darunavir will increase the level or effect of fesoterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flecainide",
            "description": {
                "common": "darunavir will increase the level or effect of flecainide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluconazole",
            "description": {
                "common": "fluconazole will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fludrocortisone",
            "description": {
                "common": "darunavir will increase the level or effect of fludrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flunisolide inhaled",
            "description": {
                "common": "darunavir will increase the level or effect of flunisolide inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluoxetine",
            "description": {
                "common": "darunavir will increase the level or effect of fluoxetine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest feasible initial or maintenance dose). Monitor for antidepressant response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "flurazepam",
            "description": {
                "common": "darunavir increases levels of flurazepam by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use alternatives if available. Consider lowering benzodiazepine dose."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluticasone furoate",
            "description": {
                "common": "darunavir will increase the level or effect of fluticasone furoate by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inhibitors may increase fluticasone systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluticasone inhaled",
            "description": {
                "common": "darunavir will increase the level or effect of fluticasone inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Strong CYP3A4 inhibitors may increase fluticasone systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvastatin",
            "description": {
                "common": "darunavir will increase the level or effect of fluvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. For HMG-CoA reductase inhibitors that are not contraindicated with darunavir, start with the lowest recommended dose and titrate while monitoring for safety."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fluvoxamine",
            "description": {
                "common": "fluvoxamine will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "darunavir will increase the level or effect of fosamprenavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosaprepitant",
            "description": {
                "common": "fosaprepitant will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fosphenytoin",
            "description": {
                "common": "fosphenytoin will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "fostamatinib",
            "description": {
                "common": "darunavir will increase the level or effect of fostamatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong CYP3A4 inhibitors may increase exposure to R406 (fostamatinib major active metabolite). Monitor for toxicities that may require fostamatinib dose reduction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "garlic",
            "description": {
                "common": "garlic decreases levels of darunavir by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gefitinib",
            "description": {
                "common": "darunavir increases levels of gefitinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration of strong CYP3A4 inhibitors may increase risk for gefitinib adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "darunavir decreases effects of glimepiride by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "darunavir, glipizide. Other (see comment). Use Caution/Monitor. \nComment: Darunavir may increase or decrease levels of glipizide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "darunavir decreases effects of glyburide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "grapefruit",
            "description": {
                "common": "grapefruit will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "green tea",
            "description": {
                "common": "green tea, darunavir. Other (see comment). Use Caution/Monitor. \nComment: Combination may increase risk of bleeding."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "griseofulvin",
            "description": {
                "common": "griseofulvin will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "guanfacine",
            "description": {
                "common": "darunavir will increase the level or effect of guanfacine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong or moderate CYP3A4 inhibitors significantly increase guanfacine plasma concentrations. FDA-approved labeling for extended-release (ER) guanfacine recommends that, if coadministered, the guanfacine dosage should be decreased to half of the recommended dose. Specific recommendations for immediate-release (IR) guanfacine are not available. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "haloperidol",
            "description": {
                "common": "darunavir will increase the level or effect of haloperidol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocodone",
            "description": {
                "common": "darunavir will increase the level or effect of hydrocodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with CYP3A4 inhibitors may increase hydrocodone plasma concentrations and can result in potentially fatal respiratory depression"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydrocortisone",
            "description": {
                "common": "darunavir will increase the level or effect of hydrocortisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "hydroxyprogesterone caproate (DSC)",
            "description": {
                "common": "darunavir will increase the level or effect of hydroxyprogesterone caproate (DSC) by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ifosfamide",
            "description": {
                "common": "darunavir will decrease the level or effect of ifosfamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Use alternatives if available. May decrease formation to active metabolite and increase toxicity of active metabolite"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "iloperidone",
            "description": {
                "common": "darunavir will increase the level or effect of iloperidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "imipramine",
            "description": {
                "common": "darunavir will increase the level or effect of imipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest feasible initial or maintenance dose). Monitor for antidepressant response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "indinavir",
            "description": {
                "common": "darunavir will increase the level or effect of indinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin aspart",
            "description": {
                "common": "darunavir decreases effects of insulin aspart by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec",
            "description": {
                "common": "darunavir decreases effects of insulin degludec by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. HIV protease inhibitors may cause new onset diabetes mellitus (DM), exacerbate existing DM, and cause hyperglycemia due to insulin resistance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin degludec/insulin aspart",
            "description": {
                "common": "darunavir decreases effects of insulin degludec/insulin aspart by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. HIV protease inhibitors may cause new onset diabetes mellitus (DM), exacerbate existing DM, and cause hyperglycemia due to insulin resistance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin detemir",
            "description": {
                "common": "darunavir decreases effects of insulin detemir by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glargine",
            "description": {
                "common": "darunavir decreases effects of insulin glargine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin glulisine",
            "description": {
                "common": "darunavir decreases effects of insulin glulisine by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin inhaled",
            "description": {
                "common": "darunavir decreases effects of insulin inhaled by pharmacodynamic antagonism. Modify Therapy/Monitor Closely. HIV protease inhibitors may cause new onset diabetes mellitus (DM), exacerbate existing DM, and cause hyperglycemia due to insulin resistance."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin lispro",
            "description": {
                "common": "darunavir decreases effects of insulin lispro by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin NPH",
            "description": {
                "common": "darunavir decreases effects of insulin NPH by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "insulin regular human",
            "description": {
                "common": "darunavir decreases effects of insulin regular human by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isoniazid",
            "description": {
                "common": "isoniazid will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "istradefylline",
            "description": {
                "common": "darunavir will increase the level or effect of istradefylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Do not exceed istradefylline 20 mg/day if coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "itraconazole",
            "description": {
                "common": "itraconazole, darunavir.\nEither increases effects of the other by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. When coadministration of itraconazole with darunavir/ritonavir is required,  itraconazole should not exceed 200 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ivacaftor",
            "description": {
                "common": "darunavir will increase the level or effect of ivacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce ivacaftor dose if coadministered with strong CYP3A4 inhibitors. See specific ivacaftor-containing product for precise dosage modification."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ixabepilone",
            "description": {
                "common": "darunavir will increase the level or effect of ixabepilone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ketamine",
            "description": {
                "common": "darunavir will decrease the level or effect of ketamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lacosamide",
            "description": {
                "common": "darunavir increases levels of lacosamide by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Consider decreasing lacosamide dose when coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lapatinib",
            "description": {
                "common": "darunavir will increase the level or effect of lapatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lenacapavir",
            "description": {
                "common": "lenacapavir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Lencapavir (a moderate CYP3A4 inhibitor) may increase CYP3A4 substrates initiated within 9 months after last SC dose of lenacapavir, which may increase potential risk of adverse reactions of CYP3A4 substrates. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "letermovir",
            "description": {
                "common": "letermovir increases levels of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levamlodipine",
            "description": {
                "common": "darunavir will increase the level or effect of levamlodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with moderate and strong CYP3A inhibitors results in increased systemic exposure to amlodipine and may require dose reduction. Monitor for symptoms of hypotension and edema when amlodipine is coadministered with CYP3A inhibitors to determine the need for dose adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levomilnacipran",
            "description": {
                "common": "darunavir will increase the level or effect of levomilnacipran by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Do not exceed 80 mg/day of levomilnacipran when coadministered with strong CYP3A4 inhibitors"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lidocaine",
            "description": {
                "common": "darunavir increases levels of lidocaine by decreasing metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "linagliptin",
            "description": {
                "common": "darunavir decreases effects of linagliptin by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "liraglutide",
            "description": {
                "common": "darunavir decreases effects of liraglutide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lofexidine",
            "description": {
                "common": "darunavir will increase the level or effect of lofexidine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Concomitant use of lofexidine with strong CYP2D6 inhibitors may increase lofexidine plasma levels. Monitor for symptoms of orthostasis and bradycardia if coadministered with a CYP2D6 inhibitor. Consider lofexidine dose reduction."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lopinavir",
            "description": {
                "common": "darunavir will increase the level or effect of lopinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "loratadine",
            "description": {
                "common": "darunavir will increase the level or effect of loratadine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "losartan",
            "description": {
                "common": "darunavir will increase the level or effect of losartan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumacaftor/ivacaftor",
            "description": {
                "common": "darunavir increases levels of lumacaftor/ivacaftor by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Strong CYP3A inhibitors do not impact lumacaftor exposure, but increased ivacaftor exposure by 4.3-fold. Due to the induction effect of lumacaftor on CYP3A, at steady-state the net exposure of ivacaftor is not expected to exceed that when given in the absence of lumacaftor at a dose of 150 mg q12hr (the approved dose of ivacaftor monotherapy). Therefore, no dose adjustment is necessary when CYP3A inhibitors are initiated in patients currently taking lumacaftor/ivacaftor. However, when initiating lumacaftor/ivacaftor in patients taking strong CYP3A inhibitors, reduce the dose to 1 tablet daily (lumacaftor 200 mg/ivacaftor 125 mg total daily dose) for the first week of treatment to allow for the steady-state induction effect of lumacaftor. Following this period, continue with the recommended daily dose. No dose adjustment is required for moderate or weak CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumateperone",
            "description": {
                "common": "darunavir will increase the level or effect of lumateperone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce lumateperone dose to 10.5 mg/day if coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lumefantrine",
            "description": {
                "common": "darunavir, lumefantrine. unknown mechanism. Use Caution/Monitor. Monitor for potential decrease of antimalarial efficacy or potential QT prolongation."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "maraviroc",
            "description": {
                "common": "darunavir will increase the level or effect of maraviroc by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Maraviroc is a CYP3A4 substrate. Decrease maraviroc dose to 150 mg BID when coadministered with strong CYP3A4 inhibitors"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "marijuana",
            "description": {
                "common": "marijuana will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "medroxyprogesterone",
            "description": {
                "common": "darunavir will increase the level or effect of medroxyprogesterone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "meperidine",
            "description": {
                "common": "darunavir increases levels of meperidine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mestranol",
            "description": {
                "common": "darunavir will increase the level or effect of mestranol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metformin",
            "description": {
                "common": "darunavir decreases effects of metformin by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methadone",
            "description": {
                "common": "darunavir will increase the level or effect of methadone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Carefully titrate dose when initiating buprenorphine, buprenorphine/naloxone, or methadone with patients taking darunavir/cobicstat. When initiating cobicistat in patients taking buprenorphine, buprenorphine/naloxone, or methadone, adjust dose for  buprenorphine, buprenorphine/naloxone, or methadone and monitor clinical signs and symptoms."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methylprednisolone",
            "description": {
                "common": "darunavir will increase the level or effect of methylprednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metoprolol",
            "description": {
                "common": "darunavir will increase the level or effect of metoprolol by  affecting hepatic enzyme CYP2D6 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "metronidazole",
            "description": {
                "common": "metronidazole will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mexiletine",
            "description": {
                "common": "darunavir will increase the level or effect of mexiletine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miconazole vaginal",
            "description": {
                "common": "miconazole vaginal will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mifepristone",
            "description": {
                "common": "darunavir will increase the level or effect of mifepristone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Do not exceed mifepristone 300 mg/day for Cushing syndrome when coadministered with strong CYP3A4 inhibitors"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "miglitol",
            "description": {
                "common": "darunavir decreases effects of miglitol by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mipomersen",
            "description": {
                "common": "mipomersen, darunavir.\nEither increases toxicity of the other by Other (see comment). Use Caution/Monitor. \nComment: Both drugs have potential to increase hepatic enzymes; monitor LFTs."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirtazapine",
            "description": {
                "common": "darunavir increases levels of mirtazapine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mirvetuximab soravtansine",
            "description": {
                "common": "darunavir will increase the level or effect of mirvetuximab soravtansine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with strong CYP3A4 inhibitors may increase unconjugated DM4 (a CYP3A4 substrate and the cytotoxic component of the antibody drug conjugate for mirvetuximab soravtansine) exposure, which may increase the risk of adverse reactions. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mitotane",
            "description": {
                "common": "mitotane decreases levels of darunavir by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Mitotane is a strong inducer of cytochrome P-4503A4; monitor when coadministered with CYP3A4 substrates for possible dosage adjustments."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mometasone inhaled",
            "description": {
                "common": "darunavir increases levels of mometasone inhaled by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. Increased risk of Cushing's syndrome or adrenal suppression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "mometasone, intranasal",
            "description": {
                "common": "darunavir will increase the level or effect of mometasone, intranasal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nafcillin",
            "description": {
                "common": "nafcillin will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "naldemedine",
            "description": {
                "common": "darunavir increases levels of naldemedine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor naldemedine for potential adverse effects if coadministered with strong or moderate CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nateglinide",
            "description": {
                "common": "darunavir decreases effects of nateglinide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nefazodone",
            "description": {
                "common": "nefazodone will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "darunavir will increase the level or effect of nelfinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "netupitant/palonosetron",
            "description": {
                "common": "darunavir will increase the level or effect of netupitant/palonosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Netupitant is mainly metabolized by CYP3A4; no dosage adjustment is required"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nevirapine",
            "description": {
                "common": "darunavir and nevirapine both increase  risk of immune reconstitution syndrome. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "darunavir will increase the level or effect of nicardipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nifedipine",
            "description": {
                "common": "nifedipine will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nilotinib",
            "description": {
                "common": "darunavir will increase the level or effect of nilotinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Nilotinib may require adjustment of dose or dosing interval if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nintedanib",
            "description": {
                "common": "darunavir increases levels of nintedanib by P-glycoprotein (MDR1) efflux transporter. Modify Therapy/Monitor Closely. If nintedanib adverse effects occur, management may require interruption, dose reduction, or discontinuation of therapy ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir",
            "description": {
                "common": "nirmatrelvir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nirmatrelvir/ritonavir",
            "description": {
                "common": "nirmatrelvir/ritonavir will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Patients on ritonavir- or cobicistat-containing HIV regimens should continue their treatment as indicated. Monitor for increased nirmatrelvir/ritonavir or protease inhibitor adverse events with concomitant use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "darunavir will increase the level or effect of nisoldipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oliceridine",
            "description": {
                "common": "darunavir will increase the level or effect of oliceridine by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If concomitant use is necessary, may require less frequent oliceridine dosing. Closely monitor for respiratory depression and sedation and titrate subsequent doses accordingly. If inhibitor is discontinued, consider increase oliceridine dosage until stable drug effects are achieved. Monitor for signs of opioid withdrawal. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ondansetron",
            "description": {
                "common": "darunavir will increase the level or effect of ondansetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. CYP-450 inhibitors may decrease clearance of ondansetron. However, no dosage adjustment for ondansetron is recommended"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "orlistat",
            "description": {
                "common": "orlistat will decrease the level or effect of darunavir by  inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Loss of virological control reported in HIV-infected patients taking orlistat concomitantly. Exact mechanism is unclear, but may include a drug-drug interaction that inhibits systemic absorption of the antiretroviral drug. Monitor HIV RNA levels frequently and if increased HIV viral load confirmed, discontinue orlistat."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "osilodrostat",
            "description": {
                "common": "darunavir will increase the level or effect of osilodrostat by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce dose of osilodrostat, a CYP3A4 substrate, by half when coadministered with a strong CYP3A4 inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ospemifene",
            "description": {
                "common": "darunavir increases levels of ospemifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxcarbazepine",
            "description": {
                "common": "oxcarbazepine will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "oxycodone",
            "description": {
                "common": "darunavir increases levels of oxycodone by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Oxycodone dose reduction may be warranted when coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "panobinostat",
            "description": {
                "common": "darunavir increases levels of panobinostat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce panobinostat starting dose to 10 mg if coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paricalcitol",
            "description": {
                "common": "darunavir increases levels of paricalcitol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "paroxetine",
            "description": {
                "common": "darunavir decreases levels of paroxetine by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Carefully titrate SSRI dose based on clinical  assessment of antidepressant response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pentobarbital",
            "description": {
                "common": "pentobarbital will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pimavanserin",
            "description": {
                "common": "darunavir will increase the level or effect of pimavanserin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Decrease dose to 17 mg/day if pimavanserin is coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitavastatin",
            "description": {
                "common": "darunavir will increase the level or effect of pitavastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. For HMG-CoA reductase inhibitors that are not contraindicated with darunavir, start with the lowest recommended dose and titrate while monitoring for safety."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pitolisant",
            "description": {
                "common": "darunavir will increase the level or effect of pitolisant by  affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. If coadministered with strong CYP2D6 inhibitors, initiate pitolisant at 8.9 mg/day and increase after 7 days to maximum of 17.8 mg/day. For patients currently taking pitolisant, reduce pitolisant dose by half upon initiating strong CYP2D6 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "polatuzumab vedotin",
            "description": {
                "common": "darunavir will increase the level or effect of polatuzumab vedotin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Polatuzumab undergoes catabolism to small peptides, amino acids, monomethyl auristatin E (MMAE), and unconjugated MMAE-related catabolites. MMAE is a CYP3A4 substrate. Coadministration of polatuzumab vedotin with a strong CYP3A4 inhibitor may increase unconjugated MMAE AUC, which may increase polatuzumab vedotin toxicities."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "posaconazole",
            "description": {
                "common": "posaconazole will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for increased darunavir or cobicistat adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pramlintide",
            "description": {
                "common": "darunavir decreases effects of pramlintide by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pravastatin",
            "description": {
                "common": "darunavir increases levels of pravastatin by unknown mechanism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "praziquantel",
            "description": {
                "common": "darunavir will increase the level or effect of praziquantel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisolone",
            "description": {
                "common": "darunavir will increase the level or effect of prednisolone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "prednisone",
            "description": {
                "common": "darunavir will increase the level or effect of prednisone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primaquine",
            "description": {
                "common": "darunavir will increase the level or effect of primaquine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "primidone",
            "description": {
                "common": "primidone will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone intravaginal gel",
            "description": {
                "common": "darunavir will increase the level or effect of progesterone intravaginal gel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone micronized",
            "description": {
                "common": "darunavir will increase the level or effect of progesterone micronized by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "progesterone, natural",
            "description": {
                "common": "darunavir will increase the level or effect of progesterone, natural by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "propafenone",
            "description": {
                "common": "darunavir will increase the level or effect of propafenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Clinical monitoring is recommended upon coadministration with antiarrhythmics."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quetiapine",
            "description": {
                "common": "darunavir will increase the level or effect of quetiapine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinidine",
            "description": {
                "common": "darunavir will increase the level or effect of quinidine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "quinupristin/dalfopristin",
            "description": {
                "common": "quinupristin/dalfopristin will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "repaglinide",
            "description": {
                "common": "darunavir will increase the level or effect of repaglinide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifapentine",
            "description": {
                "common": "rifapentine will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rifaximin",
            "description": {
                "common": "darunavir increases levels of rifaximin by P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ripretinib",
            "description": {
                "common": "darunavir will increase the level or effect of ripretinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with a strong CYP3A inhibitor will increase systemic exposure to ripretinib and its active metabolite (DP-5439), which may increase risk of adverse reactions."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ritonavir",
            "description": {
                "common": "darunavir will increase the level or effect of ritonavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rivaroxaban",
            "description": {
                "common": "darunavir increases levels of rivaroxaban by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Avoid concomitant use of rivaroxaban with known combined P-gp and strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropivacaine",
            "description": {
                "common": "darunavir will increase the level or effect of ropivacaine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosiglitazone",
            "description": {
                "common": "darunavir decreases effects of rosiglitazone by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rosuvastatin",
            "description": {
                "common": "darunavir will increase the level or effect of rosuvastatin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. For HMG-CoA reductase inhibitors that are not contraindicated with cobicistat, dose should not  exceed 20 mg/day."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rucaparib",
            "description": {
                "common": "rucaparib will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust dosage of CYP3A4 substrates, if clinically indicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rufinamide",
            "description": {
                "common": "rufinamide will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saquinavir",
            "description": {
                "common": "darunavir will increase the level or effect of saquinavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "saxagliptin",
            "description": {
                "common": "darunavir will increase the level or effect of saxagliptin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Limit saxagliptin dose to 2.5 mg/day when coadministered with strong CYP3A4 inhibitors"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "secobarbital",
            "description": {
                "common": "secobarbital will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sertraline",
            "description": {
                "common": "darunavir decreases levels of sertraline by Mechanism: unspecified interaction mechanism. Use Caution/Monitor. Carefully titrate SSRI dose based on clinical  assessment of antidepressant response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sildenafil",
            "description": {
                "common": "darunavir will increase the level or effect of sildenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with PDE-5 inhibitors may result in an increase in PDE-5 inhibitor-associated adverse reactions (eg, hypotension, syncope, visual disturbances and priapism)."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sirolimus",
            "description": {
                "common": "darunavir will increase the level or effect of sirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sitagliptin",
            "description": {
                "common": "darunavir decreases effects of sitagliptin by Other (see comment). Use Caution/Monitor. \nComment: Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solifenacin",
            "description": {
                "common": "darunavir will increase the level or effect of solifenacin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sorafenib",
            "description": {
                "common": "darunavir will increase the level or effect of sorafenib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "stiripentol",
            "description": {
                "common": "stiripentol, darunavir. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Stiripentol is a CYP3A4 inhibitor and inducer. Monitor CYP3A4 substrates coadministered with stiripentol for increased or decreased effects. CYP3A4 substrates may require dosage adjustment."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sufentanil SL",
            "description": {
                "common": "darunavir will increase the level or effect of sufentanil SL by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration of sufentanil SL with any CYP3A4 inhibitor may increase sufentanil plasma concentration, and, thereby increase or prolonged adverse effects, including potentially fatal respiratory depression."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sunitinib",
            "description": {
                "common": "darunavir will increase the level or effect of sunitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus",
            "description": {
                "common": "darunavir will increase the level or effect of tacrolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tacrolimus ointment",
            "description": {
                "common": "darunavir will increase the level or effect of tacrolimus ointment by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tasimelteon",
            "description": {
                "common": "darunavir will increase the level or effect of tasimelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tazemetostat",
            "description": {
                "common": "tazemetostat will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tecovirimat",
            "description": {
                "common": "tecovirimat will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tecovirimat is a weak CYP3A4 inducer. Monitor sensitive CYP3A4 substrates for effectiveness if coadministered."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "temsirolimus",
            "description": {
                "common": "darunavir will increase the level or effect of temsirolimus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "teniposide",
            "description": {
                "common": "darunavir will increase the level or effect of teniposide by  P-glycoprotein (MDR1) efflux transporter. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "terbinafine",
            "description": {
                "common": "darunavir will increase the level or effect of terbinafine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tezacaftor",
            "description": {
                "common": "darunavir will increase the level or effect of tezacaftor by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Adjust tezacaftor dosage regimen if coadministered with a strong CYP3A inhibitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "theophylline",
            "description": {
                "common": "darunavir will increase the level or effect of theophylline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiagabine",
            "description": {
                "common": "darunavir will increase the level or effect of tiagabine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tinidazole",
            "description": {
                "common": "darunavir will increase the level or effect of tinidazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tipranavir",
            "description": {
                "common": "darunavir will increase the level or effect of tipranavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tisotumab vedotin",
            "description": {
                "common": "darunavir increases levels of tisotumab vedotin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Tisotumab vedotin?s active metabolite (MMAE) is a CYP3A4 substrate. Coadministration with strong CYP3A4 inhibitors may increase unconjugated MMAE systemic exposure and increase risk of adverse effects."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolazamide",
            "description": {
                "common": "darunavir, tolazamide. Other (see comment). Use Caution/Monitor. \nComment: Darunavir may increase or decrease levels of tolazamide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolbutamide",
            "description": {
                "common": "darunavir, tolbutamide. Other (see comment). Use Caution/Monitor. \nComment: Darunavir may increase or decrease levels of tolbutamide. Use alternatives if available. Reports of hyperglycemia due to insulin resistance with protease inhibitors. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tolterodine",
            "description": {
                "common": "darunavir will increase the level or effect of tolterodine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "topiramate",
            "description": {
                "common": "topiramate will decrease the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "toremifene",
            "description": {
                "common": "darunavir increases levels of toremifene by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Metabolism of toremifene may be inhibited by drugs known to inhibit CYP3A4 hepatic enzymes."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tramadol",
            "description": {
                "common": "darunavir will increase the level or effect of tramadol by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. A decreased dose of tramadol may be required"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trazodone",
            "description": {
                "common": "darunavir will increase the level or effect of trazodone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest feasible initial or maintenance dose). Monitor for antidepressant response."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "triamcinolone acetonide injectable suspension",
            "description": {
                "common": "darunavir will increase the level or effect of triamcinolone acetonide injectable suspension by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "trimipramine",
            "description": {
                "common": "darunavir will increase the level or effect of trimipramine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ublituximab",
            "description": {
                "common": "ublituximab decreases effects of darunavir by immunosuppressive effects; risk of infection. Modify Therapy/Monitor Closely."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "umeclidinium bromide/vilanterol inhaled",
            "description": {
                "common": "darunavir will increase the level or effect of umeclidinium bromide/vilanterol inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Vilanterol is a CYP3A4 substrate; coadministration with potent CYP3A4 inhibitors may increase systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "upadacitinib",
            "description": {
                "common": "darunavir will increase the level or effect of upadacitinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Caution if upadacitinib is coadministered with strong CYP3A4 inhibitors."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "valbenazine",
            "description": {
                "common": "darunavir will increase the level or effect of valbenazine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce valbenazine dose to 40 mg once daily when coadministered with a strong CYP3A4 inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vardenafil",
            "description": {
                "common": "darunavir will increase the level or effect of vardenafil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration may increase PDE-5 inhibitor adverse effects including hypotension, syncope, visual changes, and prolonged erection; do not exceed vardenafil 2.5 mg q72hr."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "darunavir will increase the level or effect of verapamil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vilanterol/fluticasone furoate inhaled",
            "description": {
                "common": "darunavir will increase the level or effect of vilanterol/fluticasone furoate inhaled by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Fluticasone furoate and vilanterol are both CYP3A4 substrates; coadministration with potent CYP3A4 inhibitors may increase systemic exposure"
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vinblastine",
            "description": {
                "common": "darunavir will increase the level or effect of vinblastine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for hematologic or GI adverse effects that may be associated with increased systemic exposure to vinblastine. Consider temporarily withholding antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects. If the antiretroviral regimen must be withheld for a prolonged period, consider initiating a revised regimen that does not include a CYP3A or P-gp inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vincristine",
            "description": {
                "common": "darunavir will increase the level or effect of vincristine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Monitor for hematologic or GI adverse effects that may be associated with increased systemic exposure to vincristine. Consider temporarily withholding antiretroviral regimen in patients who develop significant hematologic or gastrointestinal side effects. If the antiretroviral regimen must be withheld for a prolonged period, consider initiating a revised regimen that does not include a CYP3A or P-gp inhibitor. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "voriconazole",
            "description": {
                "common": "voriconazole will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Coadministration with voriconazole is not recommended unless the benefit/risk assessment justifies the use."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "vortioxetine",
            "description": {
                "common": "darunavir will increase the level or effect of vortioxetine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "warfarin",
            "description": {
                "common": "darunavir, warfarin. Other (see comment). Use Caution/Monitor. \nComment: Warfarin serum concentrations may be increased or decreased. Darunavir may increase levels the less potent R-enantiomer of warfarin, but is used in combination with ritonavir which may decrease R-warfarin levels. ."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zafirlukast",
            "description": {
                "common": "zafirlukast will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zanubrutinib",
            "description": {
                "common": "darunavir will increase the level or effect of zanubrutinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Modify Therapy/Monitor Closely. Reduce zanubrutinib (a CYP3A4 substrate) to 80 mg PO BID when coadministered with a moderate CYP3A4 inhibitor. Interrupt dose as recommended for adverse reactions. After discontinuing the CYP3A4 inhibitor, resume previous zanubrutinib dose. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "zileuton",
            "description": {
                "common": "darunavir increases levels of zileuton by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Monitor. Potential for increased toxicity. ."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "acetazolamide",
            "description": {
                "common": "acetazolamide will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alfentanil",
            "description": {
                "common": "darunavir will increase the level or effect of alfentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "aliskiren",
            "description": {
                "common": "darunavir will increase the level or effect of aliskiren by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "alosetron",
            "description": {
                "common": "darunavir will increase the level or effect of alosetron by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "anastrozole",
            "description": {
                "common": "anastrozole will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "armodafinil",
            "description": {
                "common": "darunavir will increase the level or effect of armodafinil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "atazanavir",
            "description": {
                "common": "darunavir will increase the level or effect of atazanavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bexarotene",
            "description": {
                "common": "darunavir will increase the level or effect of bexarotene by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "bosentan",
            "description": {
                "common": "darunavir will increase the level or effect of bosentan by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cevimeline",
            "description": {
                "common": "darunavir will increase the level or effect of cevimeline by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "darunavir will increase the level or effect of clarithromycin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "cyclophosphamide",
            "description": {
                "common": "cyclophosphamide will increase the level or effect of darunavir by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dapsone",
            "description": {
                "common": "darunavir will increase the level or effect of dapsone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "docetaxel",
            "description": {
                "common": "darunavir will increase the level or effect of docetaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "donepezil",
            "description": {
                "common": "darunavir will increase the level or effect of donepezil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "dutasteride",
            "description": {
                "common": "darunavir will increase the level or effect of dutasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "efavirenz",
            "description": {
                "common": "darunavir will increase the level or effect of efavirenz by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eplerenone",
            "description": {
                "common": "darunavir will increase the level or effect of eplerenone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "escitalopram",
            "description": {
                "common": "darunavir will increase the level or effect of escitalopram by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Coadministration with SSRIs, TCAs, or trazodone may require dose titration of antidepressant to desired effect (eg, using the lowest feasible initial or maintenance dose). Monitor for antidepressant response."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "eucalyptus",
            "description": {
                "common": "darunavir will increase the level or effect of eucalyptus by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "finasteride",
            "description": {
                "common": "darunavir will increase the level or effect of finasteride by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "galantamine",
            "description": {
                "common": "darunavir will increase the level or effect of galantamine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ganaxolone",
            "description": {
                "common": "darunavir, ganaxolone. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. Changes in ganaxolone exposures when coadministered with strong, moderate, or weak CYP3A4 inhibitors are not expected to be clinically significant."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "imatinib",
            "description": {
                "common": "darunavir will increase the level or effect of imatinib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "isradipine",
            "description": {
                "common": "darunavir will increase the level or effect of isradipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ixazomib",
            "description": {
                "common": "darunavir, ixazomib. affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown. In clinical trials, coadministration of ixazomib with strong CYP3A inhibitors did not result in a clinically meaningful change in the systemic exposure of ixazomib."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "levoketoconazole",
            "description": {
                "common": "darunavir will increase the level or effect of levoketoconazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "montelukast",
            "description": {
                "common": "darunavir will increase the level or effect of montelukast by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nifedipine",
            "description": {
                "common": "darunavir will increase the level or effect of nifedipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nimodipine",
            "description": {
                "common": "darunavir will increase the level or effect of nimodipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "nitrendipine",
            "description": {
                "common": "darunavir will increase the level or effect of nitrendipine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "oxybutynin",
            "description": {
                "common": "darunavir will increase the level or effect of oxybutynin by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel",
            "description": {
                "common": "darunavir will increase the level or effect of paclitaxel by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "paclitaxel protein bound",
            "description": {
                "common": "darunavir will increase the level or effect of paclitaxel protein bound by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "parecoxib",
            "description": {
                "common": "darunavir will increase the level or effect of parecoxib by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "pioglitazone",
            "description": {
                "common": "darunavir will increase the level or effect of pioglitazone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "quinine",
            "description": {
                "common": "darunavir will increase the level or effect of quinine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "rabeprazole",
            "description": {
                "common": "darunavir will increase the level or effect of rabeprazole by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ramelteon",
            "description": {
                "common": "darunavir will increase the level or effect of ramelteon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "sufentanil",
            "description": {
                "common": "darunavir will increase the level or effect of sufentanil by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vincristine liposomal",
            "description": {
                "common": "darunavir will increase the level or effect of vincristine liposomal by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "vinorelbine",
            "description": {
                "common": "darunavir will increase the level or effect of vinorelbine by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zaleplon",
            "description": {
                "common": "darunavir will increase the level or effect of zaleplon by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "darunavir will increase the level or effect of ziprasidone by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zolpidem",
            "description": {
                "common": "darunavir will increase the level or effect of zolpidem by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        },
        {
            "classification_type": "Minor",
            "interaction_with": "zonisamide",
            "description": {
                "common": "darunavir will increase the level or effect of zonisamide by  affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unknown."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Increased total cholesterol",
            "percent": "10-25"
        },
        {
            "name": "Increased triglycerides",
            "percent": "3-10"
        },
        {
            "name": "Diarrhea",
            "percent": "9"
        },
        {
            "name": "Headache",
            "percent": "7"
        },
        {
            "name": "Rash",
            "percent": "6"
        },
        {
            "name": "Abdominal pain",
            "percent": "6"
        },
        {
            "name": "Nausea",
            "percent": "4"
        },
        {
            "name": "Vomiting",
            "percent": "2"
        },
        {
            "name": "Anorexia",
            "percent": "2"
        },
        {
            "name": "Fatigue",
            "percent": null
        },
        {
            "name": "Gastrointestinal disorders",
            "percent": null
        },
        {
            "name": "Acute pancreatitis",
            "percent": null
        },
        {
            "name": "dyspepsia",
            "percent": null
        },
        {
            "name": "flatulence",
            "percent": null
        },
        {
            "name": "General disorders and administration site Conditions",
            "percent": null
        },
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Hepatobiliary disorders",
            "percent": null
        },
        {
            "name": "Acute hepatitis",
            "percent": null
        },
        {
            "name": "eg",
            "percent": null
        },
        {
            "name": "cytolytic hepatitis",
            "percent": null
        },
        {
            "name": "hepatotoxicity",
            "percent": null
        },
        {
            "name": "Immune dystem disorders",
            "percent": null
        },
        {
            "name": "Hypersensitivity",
            "percent": null
        },
        {
            "name": "immune reconstitution syndrome",
            "percent": null
        },
        {
            "name": "Metabolism and nutrition disorders",
            "percent": null
        },
        {
            "name": "Diabetes mellitus",
            "percent": null
        },
        {
            "name": "hyperglycemia",
            "percent": null
        },
        {
            "name": "fat distribution",
            "percent": null
        },
        {
            "name": "Musculoskeletal and connective tissue disorders",
            "percent": null
        },
        {
            "name": "Myalgia",
            "percent": null
        },
        {
            "name": "osteonecrosis",
            "percent": null
        },
        {
            "name": "Psychiatric disorders",
            "percent": null
        },
        {
            "name": "Abnormal dreams",
            "percent": null
        },
        {
            "name": "Skin and subcutaneous tissue disorders",
            "percent": null
        },
        {
            "name": "Angioedema",
            "percent": null
        },
        {
            "name": "pruritus",
            "percent": null
        },
        {
            "name": "Stevens",
            "percent": null
        },
        {
            "name": "Johnson Syndrome",
            "percent": null
        },
        {
            "name": "urticaria",
            "percent": null
        },
        {
            "name": "Body fat redistribution",
            "percent": null
        },
        {
            "name": "Rhabdomyolysis",
            "percent": null
        },
        {
            "name": "associated with statin coadministration",
            "percent": null
        },
        {
            "name": "Toxic epidermal necrolysis and acute generalized exanthematous pustulosis",
            "percent": null
        },
        {
            "name": "Drug rash with eosinophilia and systemic symptoms",
            "percent": null
        }
    ]
}